This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Leukemia-specific T cell therapy using zinc finger nuclease (ZFN) T cell editing	<i>In vitro</i> and mouse studies identified a ZFN-based method of T cell cancer therapy. In memory T cells, knockout of endogenous T cell receptors (TCRs) using ZFNs and expression of exogenous TCRs specific for the tumor antigen Wilms tumor 1 (WT1) led to T cells specific for the WT1 tumor antigen. In mice transplanted with human WT1 acute myelogenous leukemia (AML) cells, the WT1-specific T cells resulted in antitumor activity without causing graft-versus-host disease (GvHD). Next steps include validating the findings with additional TCRs. SciBX 5(15); doi:10.1038/scibx.2012.402 Published online April 12, 2012	Patent application filed in U.S. for use in cancer therapy; unavailable for licensing	Provasi, E. <i>et al. Nat. Med.</i> ; published online April 1, 2012; doi:10.1038/nm.2700 Contact: Chiara Bonini, San Raffaele Scientific Institute, Milan, Italy e-mail: bonini.chiara@hsr.it Contact: Luigi Naldini, same affiliation as above e-mail: naldini.luigi@hsr.it